Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

New Agreement

20 Jan 2005 07:01

Angle PLC20 January 2005 For Immediate Release 20 January 2005 ANGLE plc ANGLE signs Agreement with Ben Franklin Technology Partners to advance the growth of Technology Companies in Pennsylvania ANGLE plc, a leading international venture management and consulting companyfocusing on technology commercialisation today announced that it has signed aMemorandum of Understanding (MOU) with Ben Franklin Technology Partners ofSoutheastern Pennsylvania (BFTP/SEP), an internationally recognised economicdevelopment organisation, to advance the growth of technology-based companies inthe Greater Philadelphia region. Under the terms of the MOU, it is contemplated that ANGLE will commit no lessthan $5 million over five years for funding new technology spin-outs that meetits Progeny(R) requirements. This funding will be matched by BFTP/SEP - thusdoubling the leverage on ANGLE funds for creating ventures and similarlyleveraging BFTP/SEP's economic development funds. The Greater Philadelphia region is home to many of the world's most renownedacademic institutions including the University of Pennsylvania - one of theleading research universities in the United States. Collectively, the region'sacademic institutions attract more than $1 billion of research funding perannum, generating more than 200 patent applications per year. The region iswell recognised as a global leader in the bio-pharma and medical research arena. As part of the MOU, ANGLE will serve as BFTP/SEP's preferred commercialisationpartner for technologies from universities, colleges and related institutions inthe region, and become a corporate member of the Nanotechnology Institute, aninternationally recognised alliance of business, academia and government that isfacilitating the research and development and commercialisation of bio/nanoadvances. Commenting on the joint venture, Dr. Gary Evans, CEO of ANGLE's U.S. businessoperations said, "Our MOU and partnership with BFTP/SEP provides a uniqueopportunity both to extend our base of operation in the U.S. Mid-Atlantic regionand to complement an already robust technology commercialisation community. Inaddition to its formidable research capabilities, and its pre-eminentpharmaceutical industry, the region is highly regarded for developing newcutting edge research-to-commercialisation models around nanotechnology and bio/nanotechnology." "The ANGLE MOU is indicative of the synergy that occurs when distinct entitiesshare a common goal. It addresses critical management and capital needs at theearliest points in the commercialisation of new discoveries - just pasttranslational research to pre-seed, including pre-proof of concept,pre-prototype, pre-science/management team, pre-company formation. Liketechnology, this cross-Atlantic partnership has the potential to have asignificant global impact," said RoseAnn B. Rosenthal, president and CEO of BFTP/SEP. Andrew Newland, Chief Executive of ANGLE plc said, "This is a major developmentof our Ventures business in the U.S. It demonstrates the success of ourbusiness model and the leverage we generate between our Consulting and Venturesbusinesses. Our relationship with BFTP/SEP has developed from successfulconsulting work in Pennsylvania for Ben Franklin and others, including thedevelopment of the strategy for nanotechnology in the Commonwealth ofPennsylvania. We look forward to developing world-class ventures as a result ofthis expanded partnership." Notes to Editors: Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE plc floated on the Alternative Investment Market of the London StockExchange on 17 March 2004. About Ben Franklin Technology Partners of Southeastern Pennsylvania Since 1982, Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) has helped grow the region through science, technology andentrepreneurship. BFTP/SEP provides entrepreneurs and established businesses thecapital, talent, and expertise they need to compete in the global marketplace.Like its namesake, Ben Franklin invests in, builds upon and delivers solutionsthat grow communities and create wealth by supporting today's technologicalideas and tomorrow's scientific discovery. For further information: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveDawson Buck, Deputy Chief Executive Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Mar 20063:54 pmRNSBoard Change
31st Mar 20063:52 pmRNSHolding(s) in Company
29th Mar 200611:45 amRNSEGM Statement
29th Mar 20067:02 amRNSNew Venture Company
6th Mar 20067:02 amRNSPlacing
24th Jan 20067:01 amRNSChange of Adviser
24th Jan 20067:01 amRNSContract Extension
24th Jan 20067:01 amRNSInterim Results
16th Dec 20052:32 pmRNSSnr Appt at Geomerics
17th Nov 20057:02 amRNSRe US Venture -- Aberro
15th Nov 20057:03 amRNSRe Synature Ltd
11th Nov 20057:29 amRNSAppointment at Novocellus Ltd
2nd Nov 20059:41 amRNSDirector/PDMR Shareholding
25th Oct 20058:00 amRNSAppointments - UK Ventures
20th Oct 20057:00 amRNSContract Extension
17th Oct 20057:01 amRNSVentures (US) Team Expansion
1st Sep 200512:43 pmRNSHolding(s) in Company
25th Aug 20053:02 pmRNSResult of AGM
11th Aug 20055:21 pmRNSAdditional Listing
1st Aug 20057:01 amRNSDirectorate Change
20th Jul 20058:30 amRNSContract Win
6th Jul 20057:01 amRNSFinal Results
24th Jun 20058:00 amRNSRe Provexis Admission to AIM
23rd Jun 20053:13 pmRNSNotice of Results
22nd Jun 200512:45 pmRNSHolding(s) in Company
10th Jun 20057:01 amRNSJoint Research Programme
31st May 20057:02 amRNSRe Acolyte Biomedica
26th May 20057:02 amRNSTrading Update
26th May 20057:02 amRNSProvexis - Reverse Takeover
6th May 20057:00 amRNSGeomerics - New Venture Co.
29th Apr 20057:01 amRNSNew US Venture
12th Apr 20057:00 amRNSNew Contracts
23rd Mar 200512:03 pmRNSRe Provexis Limited
21st Mar 20058:51 amRNSAdditional Listing
10th Mar 200512:06 pmRNSDirector Appt to UK Ventures
18th Feb 20058:52 amRNSProvexis Reverse Takeover
11th Feb 20057:00 amRNSNew Venture Company
10th Feb 20051:30 pmRNSHolding(s) in Company
20th Jan 20057:01 amRNSNew Agreement
20th Jan 20057:00 amRNSInterim Results
18th Jan 20057:00 amRNSLaunch of US Ventures
17th Jan 200510:47 amRNSAssociate Director Appointed
7th Jan 200510:44 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.